Dyadic shares surge 19.34% premarket after CRISPR/Cas9 patent partnership with ERS Genomics.

Dyadic International Inc. surged 19.34% in premarket trading following two strategic developments: a licensing agreement for CRISPR/Cas9 technology from ERS Genomics and a partnership with Brig Bio to develop and commercialize biologics. The CRISPR deal enhances Dyadic’s genetic engineering capabilities, positioning it to improve bioproduction efficiency and scalability, while the Brig Bio collaboration secures funding for development milestones, validating its platform’s commercial potential. Both partnerships signal long-term growth opportunities in biotechnology, aligning with investor optimism despite mixed third-quarter earnings. The premarket rally reflects market anticipation of these strategic pivots, which could drive future revenue and industry relevance.